ReviewScience and technology of advanced materials2019
Toxicity and immunogenicity concerns related to PEGylated-micelle carrier systems: a review.
Review in Science and technology of advanced materials, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed.
- The avatar principle: exosomal dynamics guiding tumor adaptation and next-generation therapeutic strategies.Journal of nanobiotechnology · 2026Review
- Nanotechnology for reproductive healthcare: a comprehensive review.Journal of nanobiotechnology · 2026Review
- Synergistic Enhancement of Diosgenin Dissolution and Bioavailability via Ternary Solid Dispersions and Self-Assembled Polymeric Micelles.Drug design, development and therapy · 2026Article
- Harnessing macrophages for precision drug delivery and cancer therapy: Strategies, advances and challenges.Materials today. Bio · 2025Review
- The Ubiquitous Use of Polyethylene Glycol in Pharmaceutical Design and Development: Technological Aspects and Future Perspectives.Nanomaterials (Basel, Switzerland) · 2025Review
- Development of ROS-responsive liposomes toward targeted drug delivery.Expert opinion on drug delivery · 2025Review
- Condensate nanovaccine adjuvants augment CD8Signal transduction and targeted therapy · 2025Article
- Considering the immunogenicity of PEG: strategies for overcoming issues with PEGylated nanomedicines.Nanomedicine (London, England) · 2025Review
- Integrative cardiovascular disease therapy: Linoleic acid restriction, enhanced external counterpulsation, and emerging nanotherapies.World journal of cardiology · 2025Review
- Anti-PEG Antibodies and Their Biological Impact on PEGylated Drugs: Challenges and Strategies for Optimization.Pharmaceutics · 2025Review
- Nano-formulations in disease therapy: designs, advances, challenges, and future directions.Journal of nanobiotechnology · 2025Review
- Synergistic approach of PEGylated photothermal agent and immunomodulator in cancer immunotherapy.Nanomedicine (London, England) · 2025Review
- Why do lipid nanoparticles target the liver? Understanding of biodistribution and liver-specific tropism.Molecular therapy. Methods & clinical development · 2025Review
- Polymeric PEG-based bioorthogonal triggers for prodrug activation in breast cancer.RSC advances · 2025Article
- Antigenicity Extension: A Novel Concept Explained by the Immunogenicity of PEG.ACS bio & med chem Au · 2025Article
- Enhancing nucleic acid delivery by the integration of artificial intelligence into lipid nanoparticle formulation.Frontiers in medical technology · 2025Review
- Status Quo in the Liposome-Based Therapeutic Strategies Against Glioblastoma: "Targeting the Tumor and Tumor Microenvironment".International journal of molecular sciences · 2024Review
- Stable Polymer-Lipid Hybrid Nanoparticles Based onPharmaceutics · 2024Article
- Impact of the Hydrophilicity of Poly(sarcosine) on Poly(ethylene glycol) (PEG) for the Suppression of Anti-PEG Antibody Binding.ACS omega · 2024Article
- Convergence of nanomedicine and neutrophils for drug delivery.Bioactive materials · 2024Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polymeric-micelle carrier systems have emerged as a novel drug-carrier system and have been actively studied for anticancer drug targeting. In contrast, toxicological and immunological concerns related to not only polymeric-micelle carrier systems, but also other nanocarrier systems, have received little attention owing to researchers' focus on therapeutic effects. However, in recent clinical contexts, biopharmaceuticals' effects on immune responses have come to light, requiring that researchers substantively explore the potential negative side effects of nanocarrier systems and of therapeutic proteins in order to develop nanocarrier systems suitable for clinical use. The present review describes current insights into both toxicological and immunological issues regarding polymeric-micelle carrier systems. The review focuses on immunogenicity issues of polymeric-micelle carrier systems possessing poly(ethylene glycol) (PEG). We conclude that PEG-related immunogenicity is deeply related to characteristics of a counterpart block of PEG-conjugates, and we propose future directions for addressing this unresolved issue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.